Late radiotherapy toxicity (subcutaneous fibrosis) · health problem or population
Summary of Findings Table ‐ PBI?APBI probably leads to higher subcutaneous fibrosis (late RT toxicity) compared with WBRT (moderate certainty).
1 finding from 1 review
Disease‐specific survival · health problem or population
Summary of Findings Table ‐ PBI?APBI showed no clear difference in cause‐specific survival (C‐SS) compared with WBRT (moderate certainty).
1 finding from 1 review
Distant metastasis‐free survival · health problem or population
Summary of Findings Table ‐ PBI?APBI showed no clear difference in distant metastasis‐free survival (DM‐FS) compared with WBRT (moderate certainty).
1 finding from 1 review
Subsequent mastectomy · health problem or population
Summary of Findings Table ‐ PBI?APBI showed no clear difference in subsequent mastectomy compared with WBRT (high certainty).
1 finding from 1 review
All‐cause mortality: at 3 years · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).
1 finding from 1 review
Proportion of participants without tumour response (CR+PR) · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower proportion of participants without tumour response (CR+PR) compared with TACE (low certainty).
1 finding from 1 review
Serious adverse events · primary hepatocellular carcinoma
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Health‐related quality of life · primary hepatocellular carcinoma
1 finding from 1 review
Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).
1 finding from 1 review
Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).
1 finding from 1 review
Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).
1 finding from 1 review
Proportion of participants without serum AFP normalisation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes proportion of participants without serum AFP normalisation compared with TACE (very low certainty).
1 finding from 1 review
Overall survival: higher‐dose WBRT vs control (3000 cGy/10 daily fractions)No. of participants: 846(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules probably leads to higher overall survival: lower‐dose WBRT vs control WBRT (3000 cGy/10 daily… compared with WBRT control (moderate certainty).
2 findings from 1 review
HR 1.21 [1.04, 1.4]
Studies not reported
Moderate
HR 0.97 [0.83, 1.12]
Studies not reported
Moderate
Brain tumour response rates: complete response (CR) and partial response (PR) combinedNo. of participants: 847(6 RCTs) · patients with newly diagnosed multiple brain metastases
WBRT with radiosensitisers (radiosen) showed no clear difference in brain tumour response rates: complete response (CR) and partial… compared with WBRT alone (high certainty).
1 finding from 1 review
OR 0.84 [0.63, 1.11]
Studies not reported
High
Adverse effectsNo. of participants: 1754(9 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
High
Quality of lifeNo. of participants: 271(2 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Symptom controlNo. of participants: 1814(3 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Overall survivalNo. of participants: 2631(8 RCTs) · patients with newly diagnosed multiple brain metastases
WBRT and radiosurgery showed no clear difference in overall survivalNo. of participants: 358(2 RCTs) compared with WBRT (moderate certainty).
1 finding from 1 review
HR 0.61 [0.27, 1.39]
Studies not reported
Moderate
1‐Year overall brain control ratesNo. of participants: 400(3 RCTs) · patients with newly diagnosed multiple brain metastases
WBRT and radiosurgery leads to lower 1‐Year overall brain control ratesNo. of participants: 400(3 RCTs) compared with WBRT (high certainty).
1 finding from 1 review
HR 0.39 [0.25, 0.6]
Studies not reported
High
Adverse effectsNo. of participants: 1754(9 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
High